Sponsors developing potential therapeutics for COVID-19 should begin discussions with the US Food and Drug Administration through an investigational new drug application (IND) meeting request, the agency said in a new guidance that discourages the emergency use authorization (EUA) pathway as an initial means of contact.
Choosing the pre-IND route at the outset is a more efficient approach than seeking a pre-EUA meeting for a drug...